SANUWAVE Health Inc
OTC:SNWV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (2.5), the stock would be worth $12.54 (32% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.7 | $18.46 |
0%
|
| 3-Year Average | 2.5 | $12.54 |
-32%
|
| 5-Year Average | 3.4 | $16.96 |
-8%
|
| Industry Average | 2.1 | $10.32 |
-44%
|
| Country Average | 3 | $15.17 |
-18%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$149.5m
|
/ |
Jan 2026
$44.1m
|
= |
|
|
$149.5m
|
/ |
Dec 2026
$53.1m
|
= |
|
|
$149.5m
|
/ |
Dec 2027
$66.7m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
SANUWAVE Health Inc
OTC:SNWV
|
158.6m USD | 3.7 | 13.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 15.8 | 57.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 3.6 | 25.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 5.3 | 38 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 3.5 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 4.6 | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7 | 43.4 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 2 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 10.6 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 2.7 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 5.7 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
SANUWAVE Health Inc
Glance View
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. The company is headquartered in Suwanee, Georgia and currently employs 43 full-time employees. The company went IPO on 2008-11-07. The firm's is focused on regenerative medicine utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The firm's lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. The company intends to apply its Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions.
